



**GLOBAL  
VITILIGO  
FOUNDATION**

**2022  
Annual  
Scientific  
Symposium**

# THANK YOU TO OUR GENEROUS SPONSORS

## Diamond

\$250K+



Incyte  
Dermatology

## Gold

\$50K+



## Silver

\$25K+

abbvie

myVitiligo team

## Bronze

\$10K+

STRATA  
SKIN SCIENCES

# SYMPOSIUM SCHEDULE



Breakfast and Poster Viewing	7:00 - 8:00 AM
Welcome Message - Amit G. Pandya, MD	8:00 - 8:10 AM
Leadership Recognition	8:10 - 8:20 AM
<b>Invited Speaker</b> - John E. Harris, MD, PhD <i>Update on Vitiligo Pathogenesis and Emerging Treatments</i>	8:20 - 8:52 AM
<b>Abstract #1</b> - Kristen Bibeau, PhD, MSPH <i>Mental Health and Psychosocial Burden Among Patients Living With Vitiligo: Findings From the Global Valiant Study</i>	8:52 - 9:04 AM
<b>Abstract #2</b> - Hyun Jeong Ju, MD <i>Differential Diagnosis Of Hypopigmentation Disorders In Children: A Retrospective Study of 1,785 Children</i>	9:04 - 9:16 AM
<b>Abstract #3</b> - Christine Learned, BA <i>Vitiligo Adverse Events and Associated Medications As Reported In the U.S. Food and Drug Administration's Adverse Event Reporting System From 2016 - 2021</i>	9:16 - 9:28 AM
<b>My Vitiligo Team</b> - Heather Lapidus Glassner	9:28 - 9:38 AM
<b>Abstract #4</b> - Katie Bush, PhD <i>RECELL Autologous Cell Harvesting Device: A Review of the Science of Autologous Skin Cell Suspension and Clinical Protocol Aimed in Establishing Safety and Effectiveness for Repigmentation of Stable Vitiligo Lesions</i>	9:38 - 9:50 AM
<b>Abstract #5</b> - Libin Mathew, MBBS, BSC <i>The Voice Registry: A Vitiligo Database – Our First Year</i>	9:50 - 10:02 AM
VOICE and Immune Tolerance Network Update	10:02 - 10:12 AM
Panel Case Studies	10:12 - 10:55 AM
Meeting Wrap-Up	10:55 - 11:00 AM



# A MESSAGE FROM THE SCIENTIFIC MEETINGS CO-CHAIRS



## SCIENTIFIC MEETINGS COMMITTEE

Jung Min Bae, MD, PhD  
Marcel Bekkenk, MD, PhD  
Seemal R. Desai, MD, FAAD  
Viktoria Eleftheriadou, MD  
Samia Esmat Mohamed, MD  
Khaled Ezzedine MD, PhD  
Iltefat Hamzavi, MD  
John E. Harris, MD, PhD  
Amit G. Pandya, MD  
Davinder Parsad, MD  
Mauro Picardo, MD  
Nanja van Geel MD, PhD  
Albert Wolkerstorfer, MD, PhD

We are very pleased to welcome the vitiligo community to the 2022 GVF Annual Scientific Symposium. At last, after two years of virtual events, it is happening, live, and in-person. We are excited to welcome back the vitiligo experts from all over the world, together with patients and industry partners.

Our invited speaker Dr. John Harris will share with us the recent updates in vitiligo pathogenesis and related management. We are all finally back together in one place to reconnect, view posters, and listen to presenters from advanced vitiligo research centers all over the world. We are excited to be bringing back the vitiligo experts panel. They will discuss some interesting cases that we hope will stimulate some discussion and debate.

We hope you enjoy this year's Symposium and take home lots of ideas, insights, and hope. If you are new to the Symposium, we invite you to participate and to ask questions. Speaking up and asking questions is what helps us all advance our practice.



Samia Esmat, MD  
*Co-Chair Scientific Meetings  
Committee*



Davinder Parsad, MD  
*Co-Chair Scientific Meetings  
Committee*

# A MESSAGE FROM THE GVF PRESIDENT

On behalf of the officers, committee members and staff at the Global Vitiligo Foundation, I would like to welcome you to our first live symposium since the onset of the pandemic. Over the last two years the vitiligo community has worked hard to continue its work to increase awareness, support individuals with vitiligo and educate health care providers about this condition using virtual platforms.

However, as social creatures, there is nothing like getting together again face-to-face to renew friendships, hear other opinions, support each other emotionally, strengthen collaborations and brainstorm about new projects. I hope all of you enjoy this meeting. I look forward to meeting you and hearing your ideas and comments.

With the likelihood of several new treatments for vitiligo being approved in the near future, I can't think of a more exciting time for the vitiligo community. Let's all continue to work together to improve the lives of individuals with vitiligo worldwide!

Amit G. Pandya, MD  
*GVF President*



## THE GLOBAL VITILIGO FOUNDATION

### OFFICERS

#### PRESIDENT

Amit G. Pandya, MD

*Palo Alto Foundation Medical Group & The University of Texas Southwestern Medical Center*

#### PRESIDENT-ELECT/SECRETARY

TBD

#### IMMEDIATE PAST PRESIDENT & TREASURER

Iltefat Hamzavi, MD, FAAD

*Hamzavi Dermatology & Henry Ford Hospital*

### BOARD OF DIRECTORS

Kim Boyd

*Comerica Bank*

Seemal R. Desai, MD, FAAD

*Innovative Dermatology & The University of Texas Southwestern Medical Center*

Samia Esmat, MD

*Faculty of Medicine  
Cairo University, Egypt*

Pearl Grimes, MD, FAAD

*Vitiligo and Pigmentation Institute of Southern California*

John E. Harris, MD, PhD, FAAD

*University of Massachusetts Medical School*

Richard H. Huggins, MD

*Henry Ford Health System*

Efrem Kamen

*Pura Vida Investments & Columbia University*

Henry W. Lim, MD, FAAD

*Clarence S. Livingood &  
Henry Ford Health System*

Davinder Parsad, MD, FRCP

*Postgraduate Institute of Medical Education & Research, Chandigarh, India*

Vicki Tiaht

*Tiaht Enterprises, LLC*

### STAFF

*Technical Registration Experts, Inc.*

#### FOUNDATION ADMINISTRATOR

Kimberly J. Miller, BS

#### DIRECTOR OF SPECIAL PROJECTS

Patrick M. Dockins, MS, CAE

#### INTEGRATED COMMUNICATIONS MANAGER

Nancy Balik FitzGerald, BS

#### BOOKKEEPER

Zach Miller

#### DATABASE & TECHNICAL SUPPORT

Jeffrey Miller

#### FINANCE, ACCOUNTING

Monica MCue, MBA  
*Desmond & Ahern, Ltd.*

# SPEAKERS

SPEAKER

## AMIT G. PANDYA, MD

*Palo Alto Foundation Medical Group  
Department of Dermatology - University of Texas Southwestern  
Medical Center*

### **GVF Roles**

*President; Medical Advisory Board Chair*

**Welcome Address and Panel Moderator**



INVITED SPEAKER

## JOHN E. HARRIS, MD, PHD

*Chair of Dermatology  
Director of the Autoimmune Therapeutics Institute  
Director of the Vitiligo Clinic and Research Center*

*UMass Chan Medical School*

### **Title of Presentation:**

*Update on Vitiligo Pathogenesis and Emerging  
Treatments*



SPEAKER

## HEATHER LAPIDUS GLASSNER

*MyHealthTeam's Senior Research Director*

### **Title of Presentation:**

*Vitiligo From the Patient Perspective*

Insights from members of MyVitiligoTeam on the impact of vitiligo on daily life, its emotional and physical impact, and perceptions of current treatment options.





### **Kristen Bibeau, PhD, MSPH**

*Head of Global Epidemiology and Real-World Evidence Statistics, Incyte Corporation*

#### ***Mental Health and Psychosocial Burden Among Patients Living With Vitiligo: Findings From the Global VALIANT Study***

Kristen Bibeau, PhD, MSPH, is the Head of Global Epidemiology and Real-World Evidence Statistics at Incyte Corporation in Wilmington, DE, USA. She obtained her MSPH and PhD qualifications in epidemiology from the University of North Carolina at Chapel Hill, NC, USA. In addition to epidemiology training, she pursued formal training in the development, validation, and operationalization of Patient Reported Outcomes (PRO) using various psychometric methods.



### **Katie Bush, PhD**

*Senior VP, Scientific & Medical Affairs, AVITA Medical*

#### ***RECELL Autologous Cell Harvesting Device: A Review of the Science of Autologous Skin Cell Suspension and Clinical Protocol Aimed in Establishing Safety and Effectiveness for Repigmentation of Stable Vitiligo Lesions***

Kate Bush, PhD is an experienced scientist (20 years) in the field of regenerative medicine with expertise in skin regeneration.

She currently oversees a scientific laboratory focused on cellular transplantation techniques for vitiligo as well as other cutaneous disorders. Additionally, she leads a medical affairs department responsible for clinical trial execution and medical education on the implementation of cellular transplantation techniques.

Lastly, Dr. Bush is responsible for educating physicians on new technologies providing evidence-based research (scientific and clinical) translating benchtop research to bedside outcomes. She has numerous publications and presentations on cellular technologies focused on skin regeneration.



# ORAL ABSTRACT PRESENTERS



## Hyun Jeong Ju, MD

*Clinical Assistant Professor, St. Vincent's Hospital, College of Medicine, Catholic University of Korea*

### ***Differential Diagnosis of Hypopigmentation Disorders in Children: A Retrospective Study of 1,785 Children***

Dr. Ju is currently working as a dermatologist in a hospital in South Korea. She realized how hypopigmented skin diseases, including vitiligo, are a big concern for people with skin of color. She is interested in vitiligo and will make ceaseless efforts for her vitiligo patients.



## Christine Learned

*4th-year medical student, Albany Medical College*

### ***Vitiligo Adverse Events and Associated Medications as Reported in the US Food and Drug Administration's Adverse Event Reporting System From 2016 to 2021***

Christine Learned is a fourth-year medical student at Albany Medical College, pursuing a career in dermatology. She is currently completing a research fellowship at Tufts Medical Center's Dermatology Clinical Trials Unit. She has a particular interest in cutaneous autoimmune disorders and regularly works with vitiligo patients as part of the several ongoing studies at Tufts.



## Libin Mathew, MBBS, MRCP, BSc

*Dermatology Registrar, St John's Institute of Dermatology, London*

### ***The Voice Registry: A Vitiligo Database – Our First Year***

Mathew is a dermatology registrar at the St John's Institute of Dermatology at Guy's and St Thomas' Hospital. He completed medical school at King's College London and is presently in his 2nd year of specialty training. He is undertaking a photodermatology rotation which includes weekly photobiology, phototherapy and vitiligo clinics. He has special interests in medical dermatology, photodermatology, vitiligo and skin cancer.



# POSTERS

## 001 Amit G. Pandya, MD

Palo Alto Foundation Medical Group

### | Assessing Participants' Experiences With Vitiligo From Qualitative Interviews

Semi-structured qualitative interviews of participants (Study 1; n=36) from TRuE-V1 and TRuE-V2 clinical trials of ruxolitinib cream and participants identified by a recruiting firm (Study 2; n=23) were conducted to evaluate the burden of vitiligo and establish treatment goals. In Study 1, facial and total body vitiligo had emotional, social, and physical impacts. Participants reported  $\geq 50\%$  and  $\geq 25\%$  reductions on the facial and total Vitiligo Area Scoring Indexes (VASI), respectively, and  $\geq 3$  on the Vitiligo Noticeability Scale (VNS) as thresholds of clinically meaningful improvement. Most Study 2 participants (83%) reported that the noticeability of their facial vitiligo affected their behavior, and 44% reported emotional and mental impacts. Many (57%) reported  $\geq 50\%$  of facial repigmentation as the smallest meaningful improvement. Results indicate that facial and total body vitiligo affects participants emotionally, socially, and physically, causing them to alter their behavior. Improvements in both face and total body were important to participants.

---

## 002 Brittani Jones, BA

Henry Ford Health System Department of Dermatology

### | Factors Contributing to Exacerbation of Vitiligo during the COVID-19 Pandemic

As we continue to come through the current pandemic and for future similar crises, a holistic approach to patients with vitiligo including home-based therapies and psychosocial support for better continuity of care and more comprehensive disease management should be considered.

---

## 003 Kristen Bibeau, PhD, MSPH

Incyte Corporation

### | Assessment of Measurement Properties of the Facial and Total Vitiligo Area Scoring Index Instruments in the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) Phase 3 Studies

This study aimed to evaluate the psychometric properties of facial and total VASI (F-VASI [range, 0–3] and T-VASI [range, 0–100], respectively) using data from two phase 3 studies of ruxolitinib cream in patients with vitiligo (n=652). Among stable patients per Patient Global Impression of Change–Vitiligo (PaGIC-V) and Physician's Global Vitiligo Assessment (PhGVA), reliability was moderate to good for F-VASI (PaGIC-V/PhGVA intraclass correlation coefficient [ICC], 0.891/0.739) and T-VASI (ICC, 0.768/0.686). Both VASI instruments detected changes based on correlations with PaGIC-V/PhGVA scores (Week 24 Spearman correlation: F-VASI,  $r=0.610/r=0.501$ ; T-VASI,  $r=0.512/0.344$ ). Using PaGIC-V and PhGVA as anchors, improvement threshold ranges of 0.38–0.60 for F-VASI and 1.69–3.88 for T-VASI were considered clinically meaningful; patient exit interviews gave similar results (n=36; 0.51 and 2.40, respectively). These results indicate that F-VASI and T-VASI are reliable, valid, responsive to change, and fit-for-purpose to evaluate facial and total vitiligo.

---

## 004 Kristen Bibeau, PhD, MSPH

Incyte Corporation

### | Exploring the Natural and Treatment History of Vitiligo: Findings From the Global VALIANT Study

The VALIANT study recruited adults (aged  $\geq 18$  years) who self-reported formal diagnoses of vitiligo via an online panel in 17 countries and interviewed them regarding their natural history and patient journey with vitiligo. The demographics, clinical characteristics, and treatment history of 3541 patients with median (range) age of 38 (18–95) years, of whom 54.6% were male, are presented. Nearly half (45.2%) of patients reported high ( $>5\%$ ) body surface area (BSA) involvement. These patients were younger at the first appearance of lesions, were more likely to have a family history of vitiligo, and used a greater number of treatments than patients with  $\leq 5\%$  BSA. Patients with darker skin types or facial involvement were also more likely to have a family history or use more treatments. The data from this global survey provides a new perspective on patient experiences with the diagnosis and treatment of vitiligo.

# POSTERS

## 005 Kristen Bibeau, PhD, MSPH

Incyte Corporation

### | Diagnosis and Management of Vitiligo From the Perspectives of Patients and Healthcare Professionals: Findings From the Global VALIANT Study

The VALIANT study was conducted via an online survey in 17 countries. A total of 3541 adult patients who self-reported a vitiligo diagnosis and 1203 healthcare professionals (HCPs) who treat patients with vitiligo were interviewed. Previous misdiagnoses were reported by 44.9% of patients and encountered by 16.4% of HCPs. Top treatment goals among patients and HCPs, respectively, included reduction/cessation of spread (24.7%/18.5%) and repigmentation of affected skin (22.5%/37.2%). Patients and HCPs reported a shared frustration with the lack of effective therapies for vitiligo. Many patients (56.7%) reported being told that their vitiligo could not be treated. Similarly, 53.9% of HCPs reported their belief that patients who never treated their vitiligo were told that there is no treatment for the disease. This perception may have led some patients to cease seeking healthcare. These findings highlight the need for improved disease management strategies.

---

## 006 Camille Robinson, BS

Duke University School of Medicine

### | Assessment of Vitiligo Patients' Perceptions and Opinions about their Dermatologists

Understanding the firsthand experience of patients with vitiligo and how they perceived their first dermatologist encounter is key to improving the patient-physician relationship and properly addressing their unique concerns. Preliminary results so far indicate patient desire for more in-depth explanations of their diagnosis, as well as the need for a greater demonstration of compassion and empathy regarding the emotional impact of vitiligo.

---

## 007 Simi Cadmus, MD, MS

UT Austin/Dell Medical School

### | Psychosocial and Quality of Life Factors Associated with Depigmentation Therapy for Vitiligo

Clinicians treating individuals with vitiligo should be aware of the potential positive effects of depigmentation, as well as barriers and challenges related to this therapy.

---

## 008 Prachi Khanna, BSA

UT Austin/Dell Medical School

### | Correlation of Google Search Interest for Vitiligo with Race and Ethnicity: A Nationwide, Population-Based Study

The online search interest for vitiligo has revealed a discrepancy between the prevalence of vitiligo amongst racial/ethnic groups and the demographics associated with highest vitiligo search (Black or African American and Latino or Hispanic).

---

## 009 Frederick Manuel, MBBS, DNB

Global Skin Centre

### | Platelet Rich Plasma for Vitiligo

Platelet Rich Plasma may find a useful place in the treatment of vitiligo in the future.

---

## 010 Botir Saatov, MD, PhD

Saatov Vitiligo Clinic

### | Metabolic disorders in the pathogenesis of vitiligo and development methods of their correction

Liposomal form may be used both for the children from the first month of life and for the pregnant women and during lactation period, because liposomal form is of natural origin and designed only for external use which has recovering, antioxidant and melanogenesis stimulating effect and has no adverse effects.

# QUICK ACCESS & DOWNLOAD



## Meeting abstracts

2022 GVF ANNUAL SCIENTIFIC SYMPOSIUM



## 2022 VIS

2022.VITILIGOSYMPOSIUM.ORG



## Updated GVF website



## GVF Newsletter



## Support Groups



## Vitiligo Social Network



## World Vitiligo Day-USA

JUNE 24-26, 2022



## Children's Books

RECOMMENDATIONS



# Join Us for the 2022 TAJ Vitiligo International Symposium (VIS)

DECEMBER 9 – 11, 2022  
TAJ BANGALORE HOTEL  
BANGALORE, INDIA

**The call for abstracts is now open!**  
**Submit today.**

[2022.vitiligosymposium.org](https://2022.vitiligosymposium.org)

